BioGenCell

Pioneering revolutionary cell therapy for microvascular diseases using a patient's own blood.

Health Tech & Life Sciences
Active
Seed Netanya, Israel Founded 2008
Last updated 2026-07-26
Total raised
$18.4M
Last: Undisclosed Round 2022-05
Stage
Seed
Founded
2008
Headcount
13
HQ
Netanya, Israel
Sector
Health Tech & Life Sciences

About

BioGenCell is an Israeli biotechnology company dedicated to transforming the lives of patients with degenerative microvascular diseases through advanced personalized cell therapy treatments. The company's proprietary TRACT (Tissue Regenerative Activated Cell Therapy) technology uses a patient's own white blood cells to create a unique mixture of therapeutic cells that regenerate blood vessels, reduce inflammation, and promote tissue regeneration and healing. BioGenCell's lead product, BGC101, is currently in Phase 2/3 clinical trials for the treatment of severe limb-threatening ischemia (CLI) and chronic limb-threatening ischemia (CLTI).

Funding history · 4 rounds · $18.4M total

2022-04
A Round $16.0M
★ Marius Nacht
2019-04
Grant $1.1M
2009-10
Seed $1.0M
1969-12
Grant $250K

Headcount over time

From 6 (2020-12) to 13 (2026-07) · +7 (+117%) · 20 points · source: Finder history + radar grounding
160 2020-12 2026-07

Q&A

What is BioGenCell's primary focus?
BioGenCell is an Israeli biotechnology company focused on developing personalized cell therapy treatments for degenerative microvascular diseases using a patient's own white blood cells.
What is BioGenCell's lead product and its current clinical trial status?
BioGenCell's lead product, BGC101, is currently in Phase 2/3 clinical trials for the treatment of severe limb-threatening ischemia (CLI) and chronic limb-threatening ischemia (CLTI).
When did BioGenCell receive FDA Fast Track designation for BGC101?
In December 2024, BioGenCell received FDA Fast Track designation with expanded access for BGC101.
Who led BioGenCell's $16 million Seed round in May 2022?
BioGenCell raised a $16 million Seed round in May 2022, led by Marius Nacht.
What is BioGenCell's proprietary technology called?
BioGenCell's proprietary technology is called TRACT (Tissue Regenerative Activated Cell Therapy).
How many employees does BioGenCell currently have?
BioGenCell has 13 employees, falling within the 11-50 employee bucket.
What is the total amount of funding BioGenCell has raised to date?
BioGenCell has raised a total of $18.6 million USD.
When was BioGenCell founded?
BioGenCell was founded in 2008.

Team · 3

Yael Porat
Founder · Founder, CEO & CSTO
Eyal Peleg
Founder · Founder & CFO
Michael Belkin
Founder · Co-Founder

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesHealthcareProvidersPatientsLaboratoriesLife SciencesBiotechnology
Business model
B2B

Highlights

1 PatentsVerified

Tags

degenerative-diseasesstem-cellshospitalsdiabetestherapeuticscell-therapymedical-technologiesbiotechnologypersonalized-medicineclinicsdoctorshealthcare-providerscardiovascularimmunologyoncologyregenerative-medicinestrokecancertreatments
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websitebiogencell.net
LinkedInlinkedin.com/company/69232576
Facebookfacebook.com/www.BioGenCell.net

Identifiers & details

Legal nameBiogencell Ltd.
Founded2008
Employees (exact)13

Radar intelligence

Patents

EPO5

Publications (Crossref)

Works3

Web history (Wayback)

Domainbiogencell.net

Certificate / subdomain footprint

Subdomains8

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)514215250
Statusפעילה
Corp typeישראלית חברה פרטית
Incorporated2008-12-23
Purposeלעסוק בכל עיסוק חוקי
Liabilityמוגבלת
In violation (unfiled)no
Last annual report2024
Active charges / liens2
Registry events3 — charge (2), people (1)
Registered addressדברי חיים 16 נתניה

Recent registry events

DateEvent
2025-08-10רישום שעבוד
2025-08-10רישום שעבוד
2026-02-08עדכון דירקטורים-הסרת דירקטור